m7G-Related DNA Damage Repair Genes are Potential Biomarkers for Predicting Prognosis and Immunotherapy Effectiveness in Colon Cancer Patients

• Published in: Frontiers in genetics Vol. 13; p. 918159
• Main Authors: Chen, Shuran, Dong, Rui, Li, Yan, Zheng, Ni, Peng, Guisen, Lu, Fei, Qiu, Quanwei, Wen, Hexin, Wang, Yitong, Wu, Huazhang, Liu, Mulin
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 09.06.2022
• Subjects: colon cancer; DNA damage repair; Genetics; m 7 G; prognostic model; tumour immunity
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2022.918159

Objective: m 7 G is a post-transcriptional modification modality, however, limited research has been conducted on its role in colon cancer. DNA damage repair (DDR) is an important factor that contributes to colon cancer development, growth and chemoresistance. This study aimed to explore whether m 7 G-related DNA damage repair genes may be used as biomarkers to predict the prognosis of colon cancer patients. Methods: We use non-negative matrix factorization (NMF) to type CRC patients into. Risk models were constructed using different expression genes in two clusters. We assessed the reliability of risk models with DCA curves, and a Nomogram. Meanwhile, The receiver operating characteristic and C-index curves were used to compare the predictive significance of the constructed risk models with other studies. In additional, we examined the significance of risk models on patients’ immunity microenvironment and response to immune therapy. Finally, we used a series of cellular experiments to validate the effect of model genes on the malignant progression of CRC cells. Results: Twenty-eight m 7 G genes were obtained from the GSEA database. Multivariate Cox and LASSO Cox regression analysis was performed and eleven m 7 G-related DDR genes were identified for constructing the risk model. Survival and stage of CRC patients were worser in the high-risk group than in the low-risk group for both the training and test sets. Additionally, the different immune microenvironment status of patients in the high- and low-risk groups, suggesting that patients in the low-risk group may be more sensitive to immunotherapy, particularly immune checkpoint inhibitors. Finally, we found that depletion of ATP2A1, one of the risk genes in our model, influence the biologic behaviour of CRC cells significantly. Conclusion: The m 7 G-related DDR genes can be used as important markers for predicting patient prognosis and immunotherapy response. Our data suggest that ATP2A1 may promote the proliferation of colon cancer cells. These findings may provide new therapeutic targets for the treatment of colon cancer.